Skip to main content
  • nl
  • fr
  • en
Other official information and services: www.belgium.be
Logo of the Belgian Federal Authorities
Return to the FAMHP homepage
Your medicine and health products
  • About the FAMHP
  • Jobs
  • Publications
  • Press
  • Contact
  • Complaints
  • Webportal
  • Home
  • Human medicines
  • Veterinary medicines
    • Medicines
    • Particular products
      • Raw materials
      • Specially reglemented substances
      • Grey area
        • Biocides
        • Blood derived products
        • Consumer goods
        • Cosmetics
        • Joint commission
        • Nutrients
    • Health products
  • Information for the public
  • Notification of adverse reactions or incidents
  • Home
  • Veterinary medicines
  • Particular products
  • Grey area
  • Cosmetics
  • Medicines
    • Medicines
  • Particular products
    • Raw materials
    • Specially reglemented substances
    • Grey area
  • Health products
    • Medical devices and their accessories

Medicines for human use

 

Last updated on 09/12/2008

Notification of adverse reactions or incidents

PIL and SPC
of a medicine

(PIL: patient information leaflet SPC: summary of product characteristics)

Search

News

12/02/2019
New verification system against falsified medicines in each link in the distribution chain
12/02/2019
Practical recommendations for the new verification systems against falsified medications
30/01/2019
Flash VIG-news: LYNPARZA® (olaparib): risk of medication errors with new pharmaceutical form
29/01/2019
Notifications about anti-tampering device (ATD) or devices to prevent tampering on packaging of existing drugs that do not fall under the Falsified Medicines Directive
All news

© 2016 - FAMHP

  • Site map
  • Disclaimer
  • Complaints
  • Contact